A5045425111- Glioma Diagnosis and Treatment
- Brain Metastases and Treatment
- Meningioma and schwannoma management
- Advanced Radiotherapy Techniques
- Radiation Therapy and Dosimetry
- Lung Cancer Research Studies
- Pituitary Gland Disorders and Treatments
- Ocular Oncology and Treatments
- Neurofibromatosis and Schwannoma Cases
- Lung Cancer Treatments and Mutations
- Radiomics and Machine Learning in Medical Imaging
- Medical Imaging Techniques and Applications
- Head and Neck Surgical Oncology
- Vascular Malformations Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Radiation Detection and Scintillator Technologies
- Cancer, Hypoxia, and Metabolism
- Adrenal and Paraganglionic Tumors
- Neuroblastoma Research and Treatments
- Radiopharmaceutical Chemistry and Applications
- Advances in Oncology and Radiotherapy
- Cancer Genomics and Diagnostics
- Boron Compounds in Chemistry
- Management of metastatic bone disease
- Nonmelanoma Skin Cancer Studies
Massachusetts General Hospital
2016-2025
Harvard University
2016-2025
Mass General Brigham
2025
University of Liverpool
2024
Stanford University
2024
Radiation Oncology Associates
2003-2023
Brigham and Women's Hospital
2016-2023
Lemuel Shattuck Hospital
2023
Digital Science (United States)
2022
Center for Neuro-Oncology
2016-2021
Our group has previously published the Graded Prognostic Assessment (GPA), a prognostic index for patients with brain metastases. Updates have been refinements to create diagnosis-specific indices. The purpose of this report is present updated GPA indices in single, unified, user-friendly allow ease access and use by treating physicians.A multi-institutional retrospective (1985 2007) database 3,940 newly diagnosed metastases underwent univariate multivariate analyses factors associated...
Lung cancer is the leading cause of cancer-related mortality in United States and worldwide. As systemic therapies improve, patients with lung live longer thus are at increased risk for brain metastases. Understanding how prognosis varies across this heterogeneous patient population essential to individualize care design future clinical trials.To update current Diagnosis-Specific Graded Prognostic Assessment (DS-GPA) non-small-cell (NSCLC) The DS-GPA based on data from diagnosed between 1985...
Conventional wisdom has rendered patients with brain metastases ineligible for clinical trials fear that poor survival could mask the benefit of otherwise promising treatments. Our group previously published diagnosis-specific Graded Prognostic Assessment (GPA). Updates larger contemporary cohorts using molecular markers and newly identified prognostic factors have been published. The purposes this work are to present all updated indices in a single report guide treatment choice, stratify...
Craniopharyngiomas, primary brain tumors of the pituitary-hypothalamic axis, can cause clinically significant sequelae. Treatment with use surgery, radiation, or both is often associated substantial morbidity related to vision loss, neuroendocrine dysfunction, and memory loss. Genotyping has shown that more than 90% papillary craniopharyngiomas carry
Treatment of the tumor and dural margin with surgery sometimes radiation are cornerstones therapy for meningioma. Molecular classifications have provided insights into biology disease; however, response to treatment remains heterogeneous. In this study, we used retrospective data on 2,824 meningiomas, including molecular 1,686 tumors 100 prospective from RTOG-0539 phase 2 trial define biomarkers response. Using propensity score matching, found that gross resection was associated longer...
Radiotherapy planning involves inherent tradeoffs: the primary mission, to treat tumor with a high, uniform dose, is in conflict normal tissue sparing. We seek understand these tradeoffs on case-to-case basis, by computing for each patient database of Pareto optimal plans. A treatment plan if there does not exist another which better every measurable dimension. The set all such plans called surface. This article presents an algorithm well distributed points (convex) surface multiobjective...
BACKGROUND The leading cause of death among patients with hereditary retinoblastoma is second malignancy. Despite its high rate efficacy, radiotherapy (RT) often avoided due to fear inducing a secondary tumor. Proton RT allows for significant sparing nontarget tissue. current study compared the risk malignancy in who were treated photon and proton RT. METHODS A retrospective review was performed at Massachusetts General Hospital or Boston Children's between 1986 2011. RESULTS total 86...
BACKGROUND In this prospective study, the authors evaluated potential treatment toxicity and progression‐free survival in patients with low‐grade glioma who received proton radiation therapy. METHODS Twenty World Health Organization grade 2 were eligible for therapy enrolled a prospective, single‐arm trial of The at dose 54 Gy (relative biological effectiveness) 30 fractions. Comprehensive baseline regular post‐treatment evaluations neurocognitive function, neuroendocrine quality life (QOL)...
This phase II study was designed to determine the efficacy of mammalian target rapamycin (mTOR) inhibitor everolimus administered daily with conventional radiation therapy and chemotherapy in patients newly diagnosed glioblastoma.Patients were randomized concurrent adjuvant temozolomide or without (10 mg). The primary endpoint progression-free survival (PFS) secondary endpoints overall (OS) treatment-related toxicities.A total 171 deemed eligible for this study. Patients receive experienced...
Risk stratification of meningiomas by histopathological grade alone does not reliably predict which patients will progress/recur after treatment. We sought to determine whether preoperative imaging and clinical characteristics could and/or improve prognostication progression/recurrence (P/R). retrospectively reviewed MR CT features 144 divided into low-grade (2007 WHO I; n = 118) high-grade grades II/III; 26) groups that underwent surgery between 2002 2013 (median follow-up 49 months)....
We investigated differences in radiation-induced grade 3+ lymphopenia (G3+L), defined as an absolute lymphocyte count (ALC) nadir of <500 cells/µL, after proton therapy (PT) or X-ray (photon) (XRT) for patients with glioblastoma (GBM).